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Abstract 
Introduction: Amiodarone is an important antiarrhythmic drug used in paediatric practice, mainly in children with complex congenital 
cardiac diseases and/or severe arrhythmias. One of the side effects of amiodarone therapy is thyroid dysfunction, which is observed in 
about 20% of patients. The thyroid dysfunction may present with various forms: from subclinical changes in hormone levels to amiodarone-
induced thyrotoxicosis (AIT) and amiodarone-induced hypothyroidism (AIH).
Material and methods: We reported six patients in the age range from two weeks to 14 years, with complex congenital cardiac diseases 
and severe arrhythmias, who developed amiodarone-induced thyroid dysfunctions: thyrotoxicosis or hypothyroidism or both together. 
The clinical signs and symptoms of all thyroid dysfunctions were atypical, most patients presented with an aggravation of heart insuf-
ficiency. Our patients with thyrotoxicosis were treated with combined therapy including thionamides and corticosteroids due to the 
presentation of mixed-identified type of AIT.
Results: Currently, five patients (one patient’s status is unknown) are in biochemical and clinical euthyreosis; however, in one of them it was 
impossible to discharge amiodarone treatment. Three of them are still treated with levothyroxine, and two do not need thyroid treatment.
Conclusions: Amiodarone-induced thyroid dysfunction is usually atypical; therefore, monitoring of thyroid status before, during, and after 
amiodarone is demanded. AIH could significantly influence the development of the child, while AIT could significantly deteriorate the 
clinical status of children with complex cardiac diseases. Early and proper diagnose of AIT and AIH allows the introduction of immediate 
and appropriate treatment considering the cardiac condition of the young patient. (Endokrynol Pol 2019; 70 (5): 392–400)
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Introduction
Amiodarone, despite its side effects, including thyroid 
dysfunction, is often used in paediatric patients with 
arrhythmias associated with complex congenital heart 
defects [1, 2]. 
In 20% of patients, amiodarone may cause subclini-
cal or clinically overt hypothyroidism or hyperthy-
roidism [3]. Amiodarone can induce thyroid dysfunc-
tion via different mechanisms, such as: (1) high iodine 
content, (2) cytotoxicity to thyroid follicular cells, (3) 
autoimmunisation, and (4) inhibition of T3 production 
[4]. The influence on thyroid gland function is related 
also to the general iodine intake, previous overt or sub-
clinical thyroid diseases, and a genetic susceptibility [4].
Amiodarone-induced thyrotoxicosis (AIT) can oc-
cur as AIT type 1, AIT type 2, or AIT type 3 (mixed). 
The types differ from each other in their pathogenesis, 
which determines the required treatment. 
Amiodarone-induced thyrotoxicosis type 1 deve-
lops due to excessive thyroid hormone synthesis in-
duced by iodine overload. This type of AIT often occurs 
in patients with pre-existing thyroid gland abnormali-
ties (multinodular goitre or Graves’ disease) and is asso- 
ciated with the presence of autonomic thyroid tissue 
and the Jod-Basedow effect, according to which iodine 
is used in an uncontrolled way to synthesise thyroxine 
and triiodothyronine. Amiodarone-induced thyrotoxi-
cosis type 2 is a destructive drug-induced thyroiditis 
leading to leakage of hormones from damaged fol-
licles. AIT type 2 primarily develops in patients with ap-
parently normal thyroid gland. Amiodarone-induced 
thyrotoxicosis type 3 combines the characteristics of 
type 1 and 2, and results also from overproduction of 
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failure and supraventricular tachyarrhythmia (100 mg 
daily, five times a week, after a month 50 mg daily, 
five times a week). Before onset of the treatment, un-
derlying thyroid disease was excluded. Thyrotoxicosis 
with negative thyroid autoantibodies was diagnosed. 
Ultrasound revealed heterogeneous parenchymal echo-
genicity of the thyroid without increased vascularity. 
Treatment included discontinuation of amiodarone 
and administration of anti-thyroid drug and gluco-
corticosteroids. After a six-week period, no significant 
clinical progression was observed. At that time, lithium 
or potassium perchlorate therapy was considered, as 
well as radiotherapy with iodine-131; however, such 
therapy was impossible due to cardiac contraindica-
tions. Therefore, the decision was made to increase 
the dose of methimazole, which resulted in gradual 
improvement of the patient’s state and normalisation 
of thyroid function tests. Finally, the treatment was 
withdrawn after eight months. 
In Patient 2, a 12.8-year-old Caucasian boy with 
hypoplastic left heart syndrome (after modified Fon-
tan operations), amiodarone was administered due to 
a deterioration of his general condition (with signs of 
congestive heart failure and atrial flutter). After one 
week of the therapy, subclinical hypothyroidism was 
diagnosed, with negative thyroid autoantibodies but 
with ultrasound picture of hypoechogenic and hetero-
geneous thyroid gland, which suggested autoimmune 
thyroiditis. Levothyroxine was introduced. After one 
month of in-ward treatment the patient was discharged 
in good condition with the recommendation of taking 
amiodarone (100 mg daily, five times a week) and le-
vothyroxine (12.5 mg daily). 
After two months of the therapy with amioda-
rone in Patient 3, a 13.9-year-old Caucasian boy with 
hypertrophic cardiomyopathy with an implanted 
cardioverter defibrillator (ICD) (after aborted cardiac 
arrest at the age of 12 years, with previous episodes of 
cardiac arrhythmia), subclinical hypothyroidism oc-
curred, and levothyroxine was added to amiodarone. 
Ultrasound revealed heterogeneous thyroid gland. No 
autoantibodies were detected. Eleven months later, the 
boy’s clinical condition improved and amiodarone was 
discontinued. Subsequently, levothyroxine was also 
discontinued four months later. After half a year, hor-
monal testes revealed thyrotoxicosis without a typical 
clinical picture of hyperthyroidism. No autoantibodies 
were detected. Ultrasound revealed heterogeneous 
thyroid with solid and cystic nodules in both lobes, and 
the vascularity pattern was normal. Methimazole was 
introduced combined with prednisone. After a further 
three months the patient was admitted to hospital due 
to supraventricular tachyarrhythmia and an inappro-
priate ICD-shock rate. Because of numerous episodes 
thyroid hormones induced by the oversupply of iodine, 
as leakage of hormones due to destructive thyroiditis. 
Amiodarone-induced hypothyroidism is induced 
by the iodine load. Excessive exposition of iodine leads 
to suppression of synthesis and release of thyroid 
hormones in the Wolff-Chaikoff mechanism (an inhibi-
tion of iodide oxidation). This phenomenon in healthy 
individuals is transient and lasts up to 48–72 hours. In 
people with impaired escape phenomenon (which de-
velops between weeks 36 and 40 of pregnancy) excess 
of iodine may lead to permanent hypothyroidism.
Amiodarone could also influence thyroid func-
tion independently of iodine. Amiodarone inhibits 
5-deiodinase activity (type 1 and 2), which inhibits 
generation of triiodothyronine (T3) from thyroxine (T4) 
in peripheral tissues and pituitary, blocks intracellular 
transport of T4, and blocks T3 from receptor binding. 
The above-mentioned mechanisms, in the initial phase 
of treatment, may result in transient subclinical hypo-
thyroidism [5].
Thyroid dysfunction has a profound impact on the 
heart. Triiodothyronine has a direct effect on cardiac 
myocytes and the electrical conduction system of the 
heart by increasing beta-adrenergic receptor levels in 
myocardium, thus stimulating the sympathetic nervous 
system and increasing oxygen consumption [6].
The aim of our study was the presentation of chil-
dren with congenital heart diseases, who, at different 
ages, developed different forms of amiodarone-induced 
thyroid dysfunction.
Material and methods
We reported six patients with cardiac diseases, who 
developed amiodarone-induced thyroid dysfunc-
tions and were treated in our department in the years 
2010–2018. The clinical outcome of the thyroid dysfunc-
tion in particular patients is presented in Table I.
Three of our patients developed amiodarone-in-
duced thyrotoxicosis, which presented with no typical 
signs and symptoms but with severe heart insufficiency. 
In two of them, the periods of hyperthyroidism and 
hypothyroidism were intertwined.
Three of our patients developed amiodarone-in-
duced hypothyroidism that required immediate thy-
roxin supplementation. 
Patient 1, a 14-year-old Caucasian girl with hetero-
taxy syndrome, dextrocardia, and complex congenital 
heart defect (after modified Fontan operations), was 
admitted to hospital due to general status deterioration 
[increasing cyanosis, fatigue, vomiting, diarrhoea, and 
heart palpitations, as well as goitre (WHO stage II)]. 
She had been treated with amiodarone since the age 
of 12 years after aborted cardiac arrest due to heart 
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of rapid ventricular tachycardia, amiodarone in a dose 
of 200 mg per day was included in the treatment for life 
indications, despite persistent thyrotoxicosis, simultane-
ously the doses of prednisone and methimazole were 
modulated. Gradual improvement of symptoms was 
achieved with increasing doses of these drugs. After 
seven months of therapy, with tapered doses of both 
antithyroid and glucocorticosteroids, the therapy was 
discontinued. Finally, hypothyroidism was diagnosed, 
and levothyroxine was introduced. Amiodarone treat-
ment was continued (200 mg daily), and the patient 
was offered ablation. 
In Patient 4, 4.8-year-old Caucasian boy with con-
genital complex heart disease (after modified Fontan op-
erations), thyrotoxicosis occurred four months after the 
introduction of amiodarone due to atrial flutter. The pa-
tient did not present with typical signs and symptoms of 
hyperthyroidism. Within a five-month period, without 
treatment, thyroid function tests normalised. For more 
than four years thyroid function has been monitored 
and has remained normal; therefore, antiarrhythmic 
therapy has not been modified. However, again at the 
age of 9.10 years, thyrotoxicosis was diagnosed after 
an episode of syncope. Therefore, amiodarone was 
withdrawn resulting in euthyreosis, without additional 
treatment. One year later, due to refractory arrhythmia, 
amiodarone was again used, and thyroid function tests 
revealed subclinical hypothyreosis. After 14 months, 
and again 17 months later, two episodes of thyrotoxi-
cosis appeared. Combined treatment with amiodarone 
and methimazole was administered. Ultrasound of the 
thyroid was normal. Anti-thyroid peroxidase antibody 
(TPOAb) level was elevated (380 IU/mL; N: < 64 IU/mL), 
with negative anti-thyroglobulin antibodies (TGAb) and 
anti-thyroid-stimulating hormone receptor antibod-
ies (TRAb). The methimazole dose was increased and 
prednisone was added, resulting in the decreasing of 
free-thyroxine (fT4) (34.6 pmol/L; N: 10.0–25.0 pmol/L) 
and free-triiodothyronine (fT3) levels (5.3 pmol/L; 
N: 3.0–8.1 pmol/L), while the  thyroid stimulating hor-
mone (TSH) level remained the same (< 0.02 uIU/mL; 
N: 0.3–4.0 ulU/mL). Methimazole was adjusted to 20 mg 
daily, and prednisone was continued. During follow-up 
the patient presented with neither clinical signs nor 
symptoms of thyrotoxicosis. Finally, four months later, 
antithyroid agent and glucocorticosteroids were with-
drawn, and levothyroxine was administered due to 
hypothyroidism.
Patient 5, a female newborn (delivered at 38 weeks 
5 days of gestation) at the age of 21 days of life, after 
cardiac surgery correction of a heart defect and Patient 
6, a male newborn at the age of nine days of life (deliv-
ered at 39 weeks’ gestation) with cardiac arrhythmias 
(diagnosed prenatally in the 28th week of pregnancy) 
were consulted by a paediatric endocrinologist due 
to abnormal results of a screening test for congenital 
hypothyroidism. Tests had been performed on the 10th 
day of the children’s life and revealed elevated TSH at 
the level between 12 and 28 U/l; therefore, the results 
of the test demanded re-testing. 
At that time, Patient 5 had been continuously infused 
with amiodarone (7.5 ug/kg/min) and digoxin due to 
tachycardia since the second day of life. The thyroid 
function parameters were re-assessed at 22 and 26 days 
of age (patient 5) and revealed subclinical hypothyroid-
ism. The continuous intravenous infusion of amioda-
rone was discontinued by a consultant cardiologist on 
the 23rd day of life due to a good response to treatment 
with propranolol and digoxin. On the 26th day of life 
levothyroxine supplementation was introduced. 
The mother of Patient 6 had been receiving amio-
darone from the 28th week of pregnancy until delivery. 
Afterwards the newborn was given amiodarone from 
1 to 13 days of life because he was resistant to adenos-
ine (supraventricular tachyarrhythmia persisted after 
administration of adenosine — the first choice drug 
in these arrhythmias in children). Then the child was 
transferred to the department of cardiology, where the 
treatment was modified — amiodarone was discon-
tinued and propranolol was introduced on 14th day 
of his life). The parameters of thyroid function were 
re-assessed at 14 days of age (Patient 6) and revealed 
hypothyroidism. Levothyroxine supplementation was 
introduced, and it has been administered until now. 
Results
Currently all patients remain in constant clinical and 
biochemical euthyreosis. Patient 1 and 5 do not receive 
thyroid treatment or amiodarone. Patient 2 receives 
levothyroxine and amiodarone (at varying daily doses 
depending on periodically occurring atrial fibrillation 
episodes). Patient 4 and 6 also receive levothyroxine, 
but the results of hormonal tests allowed a gradual 
reduction of its dose. The fate of Patient 3 is unknown 
(in the last three years he did not report to the Paediatric 
or Adult Clinic).
Discussion and conclusions
In our study, we present the clinical outcome of dif-
ferent types of amiodarone-induced dysfunctions of 
thyroid gland in six patients with different cardio-
logical problems. Amiodarone is structurally similar 
to thyroxine. It contains iodine which makes 37% of 
its weight (10% is released every day as free iodine). 
Therefore, daily intake of 100 mg of amiodarone re-
sults in 3.5 mg iodine supplementation, which greatly 
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exceeds the recommended daily intake of 150–200 ug. 
Amiodarone is metabolised in the liver to desethy-
loamiodarone (DEA), which has a similar effect on 
thyroid. The excess of iodine may be a cause of both 
hypothyroidism and/or hyperthyroidism. Amiodarone 
could also influence thyroid function independently of 
iodine. Moreover, direct cytotoxic effects of amiodarone 
and its metabolite, resulting in the destruction of thy-
roid tissue and the release of thyroid hormones, may 
be the cause of hyperthyroidism. The consequences 
of amiodarone treatment can be observed during the 
treatment (usually 36 months after the onset), but also 
up to two years after its discontinuation [7].  
Among our patients, the shortest time of amioda-
rone therapy that led to thyroid impairment was seven 
days, the longest — four years and six months. In 
patient 3, discontinuation of the antiarrhythmic agent 
had led to hyperthyroidism 10 months later. Similar 
discrepancies of duration of amiodarone treatment 
in relation to thyroid impairment ranging from 12 to 
33 months of amiodarone treatment, and a mean of 
seven months after its cessation were observed by other 
authors as well [8, 9].
We observed different types of thyroid dysfunction. 
Patients 2, 3, 4, 5, and 6 presented with clinical and 
subclinical hypothyroidism. In case 2, subclinical hypo-
thyroidism initially seemed to be transient and directly 
related to the pharmacological action of amiodarone, 
but the patient remains dependent on levothyroxine 
substitution. Patient 3 developed two episodes of 
hypothyroidism with an intermediate period of hy-
perthyroidism. In case 4 we also observed episodes of 
hypothyroidism with interspersed periods of hyperthy-
roidism. Initially, the Wolff-Chaikoff effect was clearly 
observed. After transient increase of TSH with normal 
fT3 and fT4, spontaneous remission occurred. The next 
episode of hypothyroidism required levothyroxine. In 
cases 5 and 6 hypothyroidism was diagnosed based on 
the result of a screening test for congenital hypothyroid-
ism. At the time of screening, the patients remained on 
an intravenous infusion of amiodarone, which, taking 
into account the presence of the Wolff-Chaikoff effect, 
could have a significant impact on the obtained result. 
Due to an increase of TSH concentration observed in 
the control tests levothyroxine was administered.
According to the literature, transplacental trans-
port of amiodarone varies between 10 and 12% and 
desethyloamiodarone between 20 and 22%. The con-
centration of amiodarone and its metabolite is much 
smaller than in the mother, but it would be enough to 
develop hypothyroidism, resulting from excess iodine, 
the Wolff-Chaikoff effect, and the lack of a fully devel-
oped escape phenomenon [10]. This risk is definitely 
higher before 36 weeks of pregnancy (the normal effect 
of Wolff-Chaikoff develops between 36 and 40 weeks). 
The frequency of this complication may reach 20%. 
This type of hypothyroidism is transient and requires 
administration of levothyroxine in less than 50% of 
cases [11, 10].
However, hypothyroidism in the prenatal or early 
postnatal period requires special attention due to the 
relationship between the level of thyroid hormones 
and the development of the nervous system. The first 
two weeks of life are critical [12]. It is estimated that 
children whose levothyroxine supplementation was 
included between 12 and 30 days of age have an IQ 
ratio approximately 15.7 higher compared to children 
whose treatment was included after 30 days of age 
[13]. However, according to data, subclinical hypothy-
roidism, which is a consequence of the amiodarone 
therapy, rarely leads to abnormal development of the 
nervous system. A mild developmental disorder is also 
observed in children receiving amiodarone and being 
in biochemical euthyreosis, which points to a direct 
neurotoxic effect of amiodarone on the brain and the 
consequences of possible hypoxia episodes associated 
with severe cardiac condition.
Three patients (1, 3, and 4) developed AIT. Its clinical 
presentation may be atypical. This seems to be related 
to antiadrenergic action of amiodarone. To confirm the 
diagnosis, it is mandatory to detect increased levels of 
T3 and fT3 in correlation to decreased TSH levels. Ab-
normal thyroid function test may be detected although 
patient remains clinically euthyroid. 
Due to various mechanisms leading to hyperthy-
roidism during amiodarone treatment, we can distin-
guish two main types of AIT. Type 1, associated with the 
use of excess iodine for the synthesis of hormones by 
autonomic thyroid tissue; and type 2, resulting from the 
destruction of thyroid tissue and releasing hormones. In 
some cases, differentiation between type 1 and type 2 
is difficult, then we recognise type 3 — mixed.
In the differential diagnosis, we can use a number 
of parameters, although it is difficult and often does 
not lead to diagnosis of hyperthyroidism of only type 
1 or type 2. A tool that is considered to be most useful 
is Colour Flow Doppler Sonography of the Thyroid 
(CFDS). Based on CFDS features, 80% of cases can be 
classified as type 1 or 2 AIT [4, 14]. Other markers are: 
current or previous thyroid disease, level of iodine sup-
ply, level of thyroid antibodies, radioactive iodine (RAI) 
uptake, pertechnetate uptake, technetium-99 methoxy-
isobutylisonitrile (99mTc-MIBI), response to treatment, 
risk of subsequent hypothyroidism, and spontaneous 
remission of AIT [3, 14–16]. 
Our patients who had developed hyperthyroidism 
presented symptoms of both type 1 and type 2 AIT. In 
Patient 1, towards type 1 indicated stage II goitre and 
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ultrasound image suggesting an autoimmune disease. 
No history of pre-existing thyroid disease, undetect-
able autoantibodies, and correct thyroid vascularity 
suggested type 2. In Patient 3 ultrasound image and 
history of pre-existing thyroid disease were consistent 
with type 1. Undetectable antibodies and hypothy-
roidism subsequent to hyperthyroidism treatment 
indicated type 2. In Patient 4 detectable autoantibodies 
and pre-existing thyroid disease indicated type 1, but 
normal ultrasound thyroid indicated type 2. The com-
bination of the above-mentioned features allowed us 
to diagnose mixed type AIT.
Our observations confirm the results in the litera-
ture. Among the few paediatric cases of AIT described 
to date the authors also described mixed type AIT [8, 
17]. Available data and our own observations indicate 
difficulty and importance of differentiation of type of 
AIT for successful treatment . 
Based on the mechanism of AIT, we may imple-
ment goal-directed therapy. For AIT type 1 this 
is a thyroid hormone synthesis inhibitor (drug of 
choice — methimazole, dosage up to 40–60 mg/day). 
In adults it is often combined with the iodine intake 
inhibitor potassium perchlorate (adult dosage 1 g/day) 
or sodium perchlorate used for a period of 4–6 weeks 
[14]. There are no data regarding children. Type 2 AIT 
should be treated with glucocorticosteroids due to its 
anti-inflammatory and membrane-stabilising effects 
(0.5–0.7 mg/kg/day of prednisone, up to 30 mg/day) [14, 
17]. Often the initial diagnosis changes as a result of 
the lack of response to the initially applied treatment, 
targeted at a specific type of AIT [14, 17]. Each of our 
patients required treatment with both drugs, which 
confirms the mixed aetiology of AIT. 
Such observations also allow us to conclude that in 
a life-threatening clinical scenario combined therapy is 
most beneficial, even in the absence of a clear diagnosis 
of the type of AIT. In accordance with new recommen-
dations, after 4–6 weeks of treatment with a thyrostatic 
drug without effect, steroids should be introduced to 
the therapy [14]. Besides typical treatment, AIT requires 
additional pharmacotherapy and procedures.
Alternative methods of treatment of AIT (used in 
adult patients — data supporting usage in paediatric 
patients are lacking) include: lithium carbonate, radio-
active iodine therapy, plasmapheresis, total thyroidec-
tomy, and embolisation of the thyroid artery [18–20]. 
According to the latest recommendations, complete 
thyroidectomy or radioactive iodine therapy as a radical 
treatment is indicated in hyperthyroidism, regardless of 
its type, allowing rapid achievement of euthyreosis and 
possible re-inclusion of amiodarone into the treatment, 
especially in type 1 AIT [21, 14]. The special role of total 
thyroidectomy, performed in patients with a severe 
condition due to cardiac causes and not responding to 
pharmacological treatment of hyperthyroidism, with-
out first obtaining euthyroidism, is underlined [14]. 
Radioactive iodine therapy as an alternative method 
is recommended 6–12 months after discontinua-
tion of amiodarone due to decreased iodine uptake. 
However, there are reports in the literature that it is 
effective and justified not only in cases of normal or 
increased radioiodine uptake, but also in a situation 
when radioiodine uptake is lowered [18]. Few data 
indicate effectiveness of rhTSH-aided radioiodine 
therapy [4, 21]. However, the latest recommendations 
do not recommend this procedure [14].
Close follow-up of amiodarone-treated patients is 
also a very important issue. T3 and fT3 are parameters 
not only reflecting thyroid condition, but also prognos-
tic factors of treatment. T3 and fT3 correlate better with 
clinical status and therefore are crucial in diagnosis and 
treatment of amiodarone-induced thyrotoxicosis. Dur-
ing AIT treatment, changes in fT3 concentrations are 
observed, in contrast to the steady status of fT4 [22]. 
Modification of treatment should be based on T3 and 
fT3 concentration levels in correlation with the patient’s 
clinical status.
In children with complex congenital heart defects, 
thyroid dysfunction as a side effect of the treatment 
of amiodarone administrated due to various forms of 
refractory cardiac arrhythmias requires specific guide-
lines for diagnosis, treatment, and monitoring [22, 23]. 
The main issue is hyperthyroidism, which may lead to 
potentially life-threatening thyroid storm.
Hypothyroidism is usually not a serious condi-
tion and requires supplementation of levothyroxine. 
However, in very young children (below three years 
old) hypothyroidism could significantly impair psy-
chosomatic development and should be diagnosed and 
treated at once. According to the recommendations, 
close thyroid function assessment including autoan-
tibody assay and ultrasound of the gland is required 
before, every six months, and until two years after 
amiodarone treatment cessation [16]. We postulate that 
in very young children treated with amiodarone, the 
assessment of thyroid function should be done much 
more frequently with the aim of preventing impair-
ment of their development.
To summarise, our data indicate that in paediatric 
patients treated with amiodarone, monitoring of thy-
roid function is indicated, due to the risk of thyroid 
dysfunction, which often occurs asymptomatically or 
atypically but may significantly deteriorate the devel-
opment of the child and the results of cardiological 
treatment. Moreover, the results of our study underline 
that AIT in children may have atypical, mixed-identified 
form including characteristics of both types of AIT, and it 
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requires immediate and composed treatment to prevent 
the exacerbation of heart dysfunction.
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